Evidence map›Paper›PMID 20404912›Full record

ArticlePloS one2010

Inhibition of the proprotein convertases represses the invasiveness of human primary melanoma cells with altered p53, CDKN2A and N-Ras genes.

Claude Lalou, Nathalie Scamuffa, Samia Mourah, Francois Plassa, Marie-Pierre Podgorniak, Nadem Soufir, Nicolas Dumaz, Fabien Calvo, Nicole Basset-Seguin, Abdel-Majid Khatib

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Claude LalouINSERM, UMRS940, Equipe Avenir, Institut de Génétique Moléculaire, Hôpital Saint-Louis, Université Paris 7, Paris, France.
Nathalie Scamuffa
Samia Mourah
Francois Plassa
Marie-Pierre Podgorniak
Nadem Soufir
Nicolas Dumaz
Fabien Calvo
Nicole Basset-Seguin
Abdel-Majid Khatib
Hôpital Saint-Louis · FRInserm · FRUniversité Paris Cité · FRHôpital Bichat-Claude-Bernard · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAltered tumor suppressor p53 and/or CDKN2A as well as Ras genes are frequently found in primary and metastatic melanomas. These alterations were found to be responsible for acquisition of invasive and metastatic potential through their defective regulatory control of metalloproteinases and urokinase genes. METHODOLOGY/PRINCIPAL

findingsUsing primary human melanoma M10 cells with altered p53, CDKN2A and N-Ras genes, we found that inhibition of the proprotein convertases (PCs), enzymes involved in the proteolytic activation of various cancer-related protein precursors resulted in significantly reduced invasiveness. Analysis of M10 cells and their gastric and lymph node derived metastatic cells revealed the presence of all the PCs found in the secretory pathway. Expression of the general PCs inhibitor alpha1-PDX in these cells in a stable manner (M10/PDX) had no effect on the mRNA expression levels of these PCs. Whereas, in vitro digestion assays and cell transfection experiments, revealed that M10/PDX cells display reduced PCs activity and are unable to process the PCs substrates proIGF-1R and proPDGF-A. These cells showed reduced migration and invasion that paralleled decreased gelatinase MMP-2 activity and increased expression and secretion of tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2. Furthermore, these cells showed decreased levels of urokinase-type plasminogen activator receptor (uPAR) and increased levels of plasminogen activator inhibitor-1 (PAI-1).

conclusionsTaken together, these data suggest that inhibition of PCs activity results in decreased invasiveness of primary human melanoma cells despite their altered p53, CDKN2A and N-Ras genes, suggesting that PCs may serve as novel therapeutic targets in melanoma.

Indexed as

Matrix Metalloproteinase InhibitorsNeoplasm Invasivenessalpha 1-AntitrypsinGenes, p16Genes, p53Genes, rasHumansLymph NodesMatrix Metalloproteinase 2MelanomaProprotein ConvertasesStomachTumor Cells, Culturedalpha 1-Antitrypsinalpha 1-antitrypsin PortlandMatrix Metalloproteinase 2Matrix Metalloproteinase InhibitorsProprotein Convertases

Identifiers

PMID20404912
PMCPMC2852400
OpenAlexW1997930251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.